



QA.15.0.0.3

FORM 39 [RULE 150 - E(F)] APPROVAL NUMBER: T-22/DC **TEST REPORT**

ISSUED TO: Meghalayan Medical Drugs And Services Limited

REPORT NO : EFRAC/2023/DRG/RG/03402

New colony shillong, DHS, laitumkhrah, Office of the mission

ISSUE DATE : 31/10/2023

director, NHM, Shillong, East Khasi Hills Meghalaya, 793003

CUSTOMER REFERENCE : TRF

DATE : 28/09/2023 : 1 of 2

Shillongce793003:

PAGE NO

SAMPLE DETAILS

SAMPLE REGISTRATION DETAILS

Sample Name

: Cap Omeprazole- 40mg

Sample Quantity Received

80.00 Capsule

Sample Registration Date

26/10/2023

Jun-2025

Sample Submitted/Drawn by **Batch Size**

Client

N/A

Date of Expiry : 28/09/2023

Registration No

: EFRAC/2023/DRG/RG/03402

Name of Manufacturer

Sample Receipt Date

Batch No.

: MMDSL/QC-0003

Date of Mfg.

: Jul-2023

SAMPLE ANALYSIS DETAILS

Analysis Starting Date

: 27/10/2023

Analysis Completion Date

: 31/10/2023

TEST RESULT

| SL No. | TEST PARAMETER | TESTING / REF. PROCEDURE | LABEL CLAIM | UOM | ACCEPTANCE LIMIT | RESULTS |
|--------|----------------------|---------------------------|-------------|-----------|--|---|
| 1 | Assay | Indian Pharmacopoeia 2022 | 40 mg/Cap | % of L.C. | 90.0 - 110.0 | 98.41 |
| 2 | Uniformity of Weight | Indian Pharmacopoeia 2022 | - | % | (±) 7.5 | Avg wt : 257.17 mg , (-) Dev : 2.7 , (+) Dev : 4.1 |
| 3 | Dissolution | Indian Pharmacopoeia 2022 | 40 mg/Cap | % of L.C. | Acid stage : NMT 10.0 ,Buffer stage : NMT 75.0 | For acid stage : Avg : 0.0 , Min : 0.0 , Max : 0.0 , For Buffer stage : Avg : 99.30 , Min : 99.00 , Max : 99.55 |









QA.15.0.0.3

FORM 39 [RULE 150 - E(F)] APPROVAL NUMBER: T-22/DC TEST REPORT

ISSUED TO: REPORT NO : EFRAC/2023/DRG/RG/03402

Meghalayan Medical Drugs And Services Limited ISSUE DATE : 31/10/2023

New colony shillong, DHS, laitumkhrah, Office of the mission director, NHM, Shillong, East Khasi Hills Meghalaya, 793003

CUSTOMER REFERENCE: TRF

director,NHM, Shillong, East Khasi Hills Meghalaya, 793003 DATE : 28/09/2023 Shillong, 793003 PAGE NO : 2 of 2

TEST RESULT

| | | <u>-</u> | LOT INLOULT | | | |
|--------|---------------------|---------------------------|--------------|-----------|-----------------------|-----------------------|
| SL No. | TEST PARAMETER | TESTING / REF. PROCEDURE | LABEL CLAIM | UOM | ACCEPTANCE LIMIT | RESULTS |
| 4 | Identification | Indian Pharmacopoeia 2022 | - | -/^ | The principal peak in | The principal peak in |
| | | | | | the chromatogram | the chromatogram |
| | | | _A | | obtained with the | obtained with the |
| | | | and the same | | test solution should | test solution |
| | | | - A | _/ a | correspond to the | corresponds to the |
| | | | () | M. M. | peak due to | peak due to |
| | | | -7 | Y W | omeprazole in the | omeprazole in the |
| | | | | W. | chromatogram | chromatogram |
| | | (| | .0) | obtained with the | obtained with the |
| | | | | | reference solution. | reference solution. |
| 5 | Disintegration test | Indian Pharmacopoeia 2022 | J = (0 | Min./Sec. | NMT 30 Minutes | Min: 07 Min 30 Sec, |
| | | | 0 | | | Max : 09 Min 23 Sec |

In the opinion of the undersigned, the Sample referred to above <u>is of Standard Quality</u> / <u>is not of Standard Quality</u> as defined in the Act or the Rules made there under for the reasons given below:

Date : 31/10/2023

UOM : Unit of Measurement

REMARKS : The sample is tested as per test procedure shared by client and Opinion on Quality is drawn against the result obtained for

tested parameter only.

Note : This Report is valid only for use in Indian (Domestic) Market & is Not valid for use in any International Market.

-END OF THE TEST REPORT-



